Loading…
Reported covered position: Senior Legislative Assistant, U.S. House of Representatives
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Consolidated Appropriations Act, 2023
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2617 - Consolidated Appropriations Act, 2023; Provisions Related to Healthcare H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill Issues related to rare disease Issues related to patient access treatments
Inflation Reduction Act of 2022
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2025 · fourth_quarter · Q4
Patient Access to Treatments Newborn Screening for Rare Diseases
Scientific Innovation in Healthcare Gene Therapies Rare Diseases Artificial Intelligence and Data Governance
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
H.R.5376 - Inflation Reduction Act of 2022; Healthcare provisions of the bill H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill S.4348 - FDASLA Act of 2022; All provisions of the bill Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023; healthcare provisions of the bill Issues related to rare disease Issues related to patient access treatments Issues related to newborn screening Issues related to Prescription Drug User Fee Program Reauthorization
H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval
Protecting Health Care for All Patients Act of 2022
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.5376 - Inflation Reduction Act of 2022; Healthcare provisions of the bill H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill S.4348 - FDASLA Act of 2022; All provisions of the bill Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023; healthcare provisions of the bill Issues related to rare disease Issues related to patient access treatments Issues related to newborn screening Issues related to Prescription Drug User Fee Program Reauthorization
Protecting Health Care for All Patients Act of 2022
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2617 - Consolidated Appropriations Act, 2023; Provisions Related to Healthcare H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill Issues related to rare disease Issues related to patient access treatments
Food and Drug Amendments of 2022
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.5376 - Inflation Reduction Act of 2022; Healthcare provisions of the bill H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill S.4348 - FDASLA Act of 2022; All provisions of the bill Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023; healthcare provisions of the bill Issues related to rare disease Issues related to patient access treatments Issues related to newborn screening Issues related to Prescription Drug User Fee Program Reauthorization
Food and Drug Amendments of 2022
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval
American Data Privacy and Protection Act
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval
Orphan Drug COVID–19 Mitigation Act of 2022
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2617 - Consolidated Appropriations Act, 2023; Provisions Related to Healthcare H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill Issues related to rare disease Issues related to patient access treatments
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.5376 - Inflation Reduction Act of 2022; Healthcare provisions of the bill H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill S.4348 - FDASLA Act of 2022; All provisions of the bill Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023; healthcare provisions of the bill Issues related to rare disease Issues related to patient access treatments Issues related to newborn screening Issues related to Prescription Drug User Fee Program Reauthorization
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2617 - Consolidated Appropriations Act, 2023; Provisions Related to Healthcare H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill Issues related to rare disease Issues related to patient access treatments
H.R.5376 - Inflation Reduction Act of 2022; Healthcare provisions of the bill H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill S.4348 - FDASLA Act of 2022; All provisions of the bill Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023; healthcare provisions of the bill Issues related to rare disease Issues related to patient access treatments Issues related to newborn screening Issues related to Prescription Drug User Fee Program Reauthorization
H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval
2025 · third_quarter · Q3
Issues related to patient access to treatments Issues related to rare diseases such as Duchenne Muscular Dystrophy Issues related to newborn screening for rare diseases
Issues related to the Inflation Reduction Act's prescription drug provisions
Issues related to scientific innovation in healthcare such as gene therapies Issues related to artificial intelligence and data governance
Tax issues related to research and development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2025 · second_quarter · Q2
Issues related to rare diseases such as Duchenne Muscular Dystrophy Issues related to patient access to treatments Issues related to newborn screening for rare diseases
Issues related to scientific innovation in healthcare such as gene therapies Issues related to artificial intelligence and data governance
Tax issues related to research and development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2025 · first_quarter · Q1
Issues related to patient access to treatments Issues related to rare diseases such as Duchenne Muscular Dystrophy Issues related to newborn screening for rare diseases
Issues related to the Inflation Reduction Acts prescription drug provisions
Issues related to scientific innovation in healthcare such as gene therapies Issues related to artificial intelligence and data governance
Tax issues related to research and development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2024 · fourth_quarter · Q4
Issues related to the Inflation Reduction Acts prescription drug provisions
Issues related to scientific innovation in healthcare such as gene therapies Issues related to artificial intelligence and data governance
Tax issues related to research and development
Issues related to patient access to treatments Issues related to rare diseases such as Duchenne Muscular Dystrophy Issues related to newborn screening for rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2024 · third_quarter · Q3
Issues related to patient access to treatments Issues related to rare diseases, including Duchenne Muscular Dystrophy Issues related to newborn screening for rare diseases Issues related to scientific innovation in healthcare, including gene therapies Public Law 117-169, Inflation Reduction Act of 2022; Provisions related to prescription drugs
Issues related to artificial intelligence and data governance
Tax issues related to research and development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2024 · second_quarter · Q2
Issues related to artificial intelligence and data governance
Issues related to patient access to treatments Issues related to rare diseases, including Duchenne Muscular Dystrophy Issues related to newborn screening for rare diseases Issues related to scientific innovation in healthcare, including gene therapies Public Law 117-169, Inflation Reduction Act of 2022; Provisions related to prescription drugs
Tax issues related to research and development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2024 · first_quarter · Q1
Issues related to artificial intelligence and data governance
Issues related to patient access to treatments Issues related to rare diseases, including Duchenne Muscular Dystrophy Issues related to newborn screening for rare diseases Issues related to scientific innovation in healthcare, including gene therapies Public Law 117-169, Inflation Reduction Act of 2022; Provisions related to prescription drugs
Tax issues related to research and development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2023 · fourth_quarter · Q4
Tax issues related to research and development
Issues related to patient access to treatments Issues related to rare diseases Issues related to newborn screening Issues related to scientific innovation in healthcare Public Law 117-169, Inflation Reduction Act of 2022; Provisions related to prescription drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2023 · third_quarter · Q3
Issues related to patient access to treatments Issues related to rare diseases Issues related to newborn screening Issues related to scientific innovation in healthcare Public Law 117-169, Inflation Reduction Act of 2022; Provisions related to prescription drugs
Tax issues related to research and development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2023 · second_quarter · Q2
Tax issues related to research and development
Public Law 117-169, Inflation Reduction Act of 2022; Provisions related to prescription drugs Issues related to patient access to treatments Issues related to rare diseases Issues related to newborn screening Issues related to scientific innovation in healthcare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2023 · first_quarter · Q1
Issues related to patient access to treatments Issues related to rare diseases Issues related to newborn screening
Tax issues related to research and development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2022 · fourth_quarter · Q4
H.R.2617 - Consolidated Appropriations Act, 2023; Provisions Related to Healthcare H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill Issues related to rare disease Issues related to patient access treatments
Tax issues related to research and development
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2022 · third_quarter · Q3
Tax issues related to research and development
H.R.5376 - Inflation Reduction Act of 2022; Healthcare provisions of the bill H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill S.4348 - FDASLA Act of 2022; All provisions of the bill Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023; healthcare provisions of the bill Issues related to rare disease Issues related to patient access treatments Issues related to newborn screening Issues related to Prescription Drug User Fee Program Reauthorization
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2022 · second_quarter · Q2
H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval
Tax issues related to research and development
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE